Menlo Park -Based Auxogyn Raises $18 Million in Second Round

Menlo Park, Calif. -- Auxogyn, a Menlo Park-based developer of technology focused on women's reproductive health, said on Tuesday it has raised $18 million in its second round of funding, led by new investor SR One. Previous backers Kleiner Perkins Caufield and Byers, TPG Biotech and Merck Serono Ventures also participated in the round, which the company will use to support regulatory clearance and commercial launch of its non-invasive test designed to determine the viability of embryos during in vitro fertilization (IVF) procedures. "We look forward to securing CE Mark and subsequently introducing Eeva commercially in Europe during the second half of 2012," said Lissa Goldenstein, the president and CEO of Auxogyn
http://www.auxogyn.com 
http://www.auxogyn.com/assets/press-releases/2012-06-05.series-b-financing.pdf